[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Waning vaccine efficacy in the UK", "description": "Beijing, 70 cases since Friday\n\nThree P.C.R. tests over five days\n\nzero Covid strategy\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1070356/Vaccine-surveillance-report-week-16.pdf\n\nEffectiveness against symptomatic disease \n\nAfter 2 doses of the AstraZeneca\n\nAgainst the Omicron variant\n\nStarts at 45 to 50%\n\nDrops to almost no effect, 25 weeks after the second dose\n\nWith 2 doses of Pfizer or Moderna\n\nEffectiveness dropped from around 65 to 70%\n\nDown to around 15% by 25 weeks after the second dose\n\nTwo to 4 weeks after a booster dose\n\nEffectiveness ranges from around 60 to 75%\n\nDropping to almost no effect from 20+ weeks after the booster\n\n Effectiveness against hospitalisation \n\nAlpha and Delta variants\n\nHigher levels of protection against hospitalisation with all vaccines\n\nOmicron\n\n18 to 64 year olds\n\nAll COVID-19 cases admitted via emergency care\n\nVE after a booster peaked at 82.4%\n\nDropped to 53.6% by 15+ weeks after the booster\n\nNeeded oxygen/ventilated\n\nVE 97.1% down to 75.9%\n\nAlso\n\nOmicron generally causes milder disease,\nin particular among younger individuals\n\nAll individuals who are hospitalised are tested for COVID-19\nAn increasing proportion of individuals hospitalised with a positive COVID- 19 test are likely to have COVID-19 as an incidental finding rather than the primary reason for admission. \n\nAll 3 vaccines give similar protection against hospitalisation\n\nEffectiveness against mortality \n\nAlpha and Delta\n\nOver 90% protection against mortality with all 3 vaccines\n\nVaccine effectiveness against mortality with Omicron\n\nAt 25-plus weeks following the second dose, \nvaccine effectiveness was around 60%", "link": "https://www.youtube.com/watch?v=01qdCw2cMzg", "date_published": "2022-04-26 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]